15 October 2024 - Because of the direct link between diagnosis and therapy, the data from the early benefit assessment ...
2 September 2024 - In the two manufacturer studies, important patient-relevant outcomes were not recorded. ...
10 August 2024 - Policy declarations from the G7 and other high-level meetings call for increased incentives for antimicrobial research and ...
1 July 2024 - For the first time, IQWiG has evaluated a drug that is a diagnostic agent within the ...
2 April 2024 - Roche designed its trial for both approval and health technology assessments but the analyses planned for ...
1 March 2024 - Patients with inoperable or metastatic uveal melanoma survive longer with the new therapy than with other therapy ...
1 March 2024 - In 2023, IQWiG found an additional benefit of vutrisiran compared to patisiran sodium based on a study. ...
1 February 2024 - In a dossier assessment in 2023, an additional benefit could not yet be proven due to unclear ...
18 January 2024 - Since July 2023, there has been one in Germany for patients who suffer from acute myeloid leukaemia ...
1 December 2023 - Two small RCTs with children of different ages together make it possible to make one statement: the ...
15 November 2023 - Two randomised controlled studies in the third and fourth lines for colorectal and breast cancer each show ...
4 October 2023 - Even in the final report, many questions about the treatment of relapsing-remitting multiple sclerosis remain unanswered because ...
6 October 2023 - In a statement to the EMA, the IQWiG emphasised that single-arm studies may be sufficient for ...
5 October 2023 - Due to legal requirements, the Federal Joint Committee (G-BA) has completed the re-evaluation process for belantamab mafodotin ...
19 September 2023 - Fundamental revision of the cost benefit assessment and addition of the concept of application-accompanying data collection. ...